J&J's Imaavy demonstrates long-term disease control in myasthenia gravis

J&J's Imaavy demonstrates long-term disease control in myasthenia gravis

J&J’s Imaavy (nipocalimab) shows sustained gMG improvements through 120 weeks, cutting IgG by 64% and boosting symptom control. Read more here.

IMAAVY (nipocalimab)shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)

Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained minimal symptom expression (MSE) experienced greater improvements in quality of life than those with transient MSE in a post-hoc analysis of the Phase 3 study EPIC, a head-to-head study, […] The post IMAAVY (nipocalimab)shows over two…